Rhythm, Ariad, PerkinElmer, & More Boston Life Sciences Newsmakers
Summary
Rhythm, Ariad, PerkinElmer, & More Boston Life Sciences Newsmakers Xconomy Boston — Funding, clinical updates, and a new innovation center made up this week’s New England life sciences news.—And days after an SEC filing showed that Rhythm Pharmaceuticals had pulled in $9.5 million of a targeted $34.5 million round, the Boston-based company announced it was kicking off a Phase 2 trial of its novel compound RM-131 for treating gastroparesis in Type I and Type II diabetes patients.The condition impairs the stomach’s ability to move food further along the digestive tract.—And PerkinElmer (NYSE: PKI), a Waltham, MA-based provider of life sciences tools, announced it will create a Personalized Health Innovation Center of Excellence at its Hopkinton, MA, site, formerly occupied by Caliper Life Sciences, which was acquired by PerkinElmer for $600 million last year.The site will add another 100 jobs for the company and will “focus on accelerating scientific innovation to help researchers who are working to eradicate disease and extend the quality and longevity of life,” according to the announcement.
Classifications
AskAI Classifications
LabelsLinked Companies
